Yuhei YAMAGUCHI· @yymgcmd · X·· 19 小时前评分45
正文 · 机器翻译
🔥成果令人印象深刻！
但究竟是哪种药物带来了获益？
Anbenitamab 对比 HP？
还是
HB1801（白蛋白结合型 DTX）对比 DTX？
#ESMO26
32 浏览 · 1 赞 · 0 转发 · 0 回复
会议摘要
LBA15按 Proffered paper 2: Breast cancer, early and advanced stage 对上
Anbenitamab plus albumin-bound docetaxel in patients (pts) with HER2-positive advanced breast cancer (BC): A randomized phase III study
https://esmocongress.esmo.orgLBA80按 Rapid oral 1: Gastrointestinal tumour, upper digestive 对上
Anbenitamab plus chemotherapy for previously treated HER2-positive gastric or gastroesophageal carcinomas (GC/GEJC): Updated overall survival (OS) analysis of KC-WISE
https://esmocongress.esmo.orgPresented at #ESMO26: Among patients with HER2-positive advanced breast cancer, the HER2-targeted bispecific antibody anbenitamab plus albumin-bound docetaxel led to 24-month progression-free survival of 58.5%, as compared with 34.4% with standard therapy. Full phase 3 HEALER trial results: https://nej.md/4BcWlF3 Editorial: Targeting HER2 — A Triumph of Science https://nej.md/4Bh4GaF @myESMO在 X 查看被引用的帖子
来源：Yuhei YAMAGUCHI · x.com